Over the past four years, our company has made significant progress in the field of oncological active ingredient and preparation development, thanks to the support received through the project titled ´Development of innovative, high added value oncological drug preparations for personalized therapies.´ During the period from 2021 to 2024, we worked on the development of 14 active ingredients and 5 preparations in collaboration with our consortium partner, HUN-REN TTK.

he project identified as 2020-1.1.2-PIACI-KFI-2020-00039, conducted by Egis Pharmaceuticals PLC and its consortium partner, the HUN-REN Research Centre for Natural Sciences (TTK), finished on December 31, 2024.

Egis Pharmaceuticals has announced that, backed by the Hungarian Competition Authority´s official certification, it has acquired one of Hungary´s well-known, locally applied dermatological product lines from Teva Pharmaceutical Industries Ltd. This move aims to strengthen Egis´s position in the Hungarian over-the-counter (OTC) market.

The Hungarian Innovation Association, in collaboration with the Hungarian Innovation Foundation, announced the contest for the 2024 Innovation Grand Prize at the Egis Science and Technology Center. The significance of the award is highlighted by the fact that innovative companies can apply for the 33rd time for the competition, which will conclude with a ceremonial award ceremony next spring.

• mAbxience and Egis collaborate on the commercialization of two biosimilar candidates • The agreement covers eight Central and Eastern European countries with the potential for expansion into additional territories • mAbxience will serve as the marketing authorization holder, while Egis will manage commercialization in the designated regions

Two of Egis’ fixed-dose combination drugs have won the Innovation Grand Prize. The awarded Egis medicines feature significant innovations as they reduce the risk of cardiovascular events related to atherosclerosis due to the combined lipid-lowering therapy. In respect of these two products the company obtained three patents related to active ingredient development and two patents related to formulation development that are all relevant to large-scale manufacturing technologies. The recognition was not without a history, as this is the tenth time an Egis medicine has received an Innovation Prize or Grand Prize.

Continuous modernisations and investment, launch of a new line of business, tree planting, exhibitions, and a short story contest. In 2023 Egis commemorated its 110th anniversary with a special series of events.

Egis Pharmaceuticals PLC, celebrating the 110th anniversary of its foundation this year, is expanding its usual activities with new elements thanks to investments exceeding a total value of more than 100 billion HUF in Hungary over the past period.. Egis, one of the leading generic pharmaceutical companies in Eastern and Central Europe, now offers drug stubstance contract development and contract manufacturing services under the name of Egis Pharma Services to both existing and new pharmaceutical partners.

Egis and the Uzbek Medicines Authority have signed a collaboration agreement in Tashkent to improve pharmaceutical regulations and access to medicines in Uzbekistan.

The selection process for the position of Egis Group’s Commercial Director has been closed. As a result, dr Csaba Pácz remains head of the Commercial Directorate.

The predecessor of Egis Pharmaceuticals PLC, Dr Wander Pharmaceuticals and Nutriments Ltd. was registered on 19 February 1913.

Csaba Poroszlai is confirmed CEO of the company by the Board of Directors of Egis. Balázs Vándor is appointed to the position of the Company’s Chief Financial Officer.